Kaposi's Sarcoma

Ewing's sarcoma of bone

AIDS and HIV

AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for...

Viruses and cancer

Viruses are implicated in the causes of some cancers, and may in time offer potential therapy for other forms of cancer. An oncovirus is a virus that can cause cancer. Worldwide, the WHO Internati...

What is Cancer?

  Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example,...

Celgene edges higher on Abraxane melanoma study

Shares of Celgene Corp. rose Tuesday after the company said its cancer drug Abraxane slowed the progression of melanoma in a late-stage clinical trial.The trial compared Abraxane and dacarbazine in 5...

Oncology Spotlight: Abraxane May Earn Approval for Third Indication

Celgene Corp. recently released positive Phase 3 data for its cancer drug Abraxane in combination with gemcitabine (Lilly’s chemotherapy drug) for the treatment of advanced pancreatic cancer.  The...

Sarcoma Foundation of America Names Tony Ferlenda As New Chief Executive Officer

- Leading SFA's VISION 2020 Campaign to Cure Sarcoma- DAMASCUS, Md., Oct. 8, 2012 /PRNewswire-USNewswire/ -- The Sarcoma Foundation of America (SFA), an organization dedicated to finding the cure...

Celgene gets new Abraxane marketing approval

Celgene Corp. said Friday it won a new marketing approval for its drug Abraxane. The Food and Drug Administration approved it as a primary treatment for non-small cell lung cancer.Abraxane was approv...

US FDA Grants Approval For Celgene's ABRAXANE For Non-Small Cell Lung Cancer

SUMMIT (dpa-AFX) - Celgene Corporation (CELG) Friday announced that the U.S. Food and Drug Administration, or the FDA has approved ABRAXANE for the first-line treatment of locally advanced or meta...

Abraxane meets endpoint in first-line metastatic melanoma

Celgene Corp. (NASDAQ:CELG) said Abraxane nab-paclitaxel met the primary endpoint of progression-free survival (PFS) vs. dacarbazine in the Phase III CA033 trial in 529 chemotherapy-naive patients wit...

Celgene's melanoma drug Abraxane prolongs survival in study

Previously untreated patients with metastatic melanoma who received Celgene's Abraxane, or paclitaxel, achieved progression-f -More- 

Celgene seeks FDA approval of Abraxane for pancreatic cancer

Celgene plans to submit Abraxane, or paclitaxel, within the next five months for FDA approval as a treatment for pancreatic c -More- 

A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases.

Cellax is a PEGylated carboxymethylcellulose conjugate of docetaxel (DTX) which condenses into a 120-nm nanoparticle, and was compared against the approved clinical taxane nanoformulation (Abraxane®)...

Mitochondria organelle transplantation: introduction of normal epithelial mitochondria into human cancer cells inhibits proliferation and increases drug sensitivity.

Mitochondrial dysfunction of cancer cells includes increased aerobic glycolysis, elevated levels of ROS, decreased apoptosis, and resistance to chemotherapeutic agents. We hypothesized that the introd...

EXTRAMEDULLARY ORBITAL GRANULOCYTIC SARCOMA WITHOUT BONE MARROW INVOLVEMENT: A Report of Two Cases.

The authors present herein 2 extramedullary orbital granulocytic sarcoma (GS) cases without bone marrow involvement in view of their rarity and also to reevaluate the treatment approach in this diseas...

COMPARISON OF DOXORUBICIN CARDIOTOXICITY IN PEDIATRIC SARCOMA PATIENTS WHEN GIVEN WITH DEXRAZOXANE VERSUS AS CONTINUOUS INFUSION.

Doxorubicin is an effective agent for many malignancies. To limit cardiotoxicity, doxorubicin can be given as prolonged infusion (PIDX) or bolus infusion following dexrazoxane (DZX). The authors repor...

Finding the optimal balance: Challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems.

Anticancer drugs as well as nano-sized drug delivery systems face many barriers that hinder penetration deeply and evenly into solid tumors: a chaotic, tortuous vascular compartment resulting in tumor...